CellSpring
Sep 29, 2016
Bayer AG & Evotec AG’s deal; Plasticell and CellSpring AG’s deal; Allergan Acquires Akarna; Cambrex Acquires Pharmacore
Bayer AG and Evotec AG enter a multi-target research partnership agreement Bayer and Evotec have agreed to develop novel treatments for chronic kidney disease in diabetic patients. According to the agreement, Bayer will have all the rights to select clinical candidates and Evotec’s Cure Nephron target pipeline. It w...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
